Paid Clinical Trials Louisiana
Discover 826 paid clinical trials in Louisiana. Search by city or condition to find a research study near you that matches your needs across various therapeutic areas.
Maridebart CafraglutideA Study of Maridebart Cafraglutide in Adult Participants With Type 2 Diabetes Mellitus (T2DM)
Sponsor:
Amgen
Location:
Code:
NCT06660173
Conditions
Type 2 Diabetes Mellitus (T2DM)
Eligibility Criteria
Sex: All
Age: 18+
Healthy Volunteers: Not accepted
Interventions
Maridebart Cafraglutide
Placebo
LasmiditanA 12-Month Study of Lasmiditan (LY573144) Treatment in Children Aged 6 to 17 With Migraine
Sponsor:
Eli Lilly and Company
Location:
Code:
NCT04396574
Conditions
Migraine
Eligibility Criteria
Sex: All
Age: 6 - 17
Healthy Volunteers: Not accepted
Interventions
Lasmiditan
Steroids & TKIsTesting the Use of Steroids and Tyrosine Kinase Inhibitors With Blinatumomab or Chemotherapy for Newly Diagnosed BCR-ABL-Positive Acute Lymphoblastic Leukemia in Adults
Sponsor:
National Cancer Institute (NCI)
Location:
Code:
NCT04530565
Conditions
B Acute Lymphoblastic Leukemia With t(9;22)(q34.1;q11.2); BCR-ABL1
Eligibility Criteria
Sex: All
Age: 18 - 70+
Healthy Volunteers: Not accepted
Interventions
Biospecimen Collection
Blinatumomab
Bone Marrow Aspiration and Biopsy
Cyclophosphamide
Cytarabine
CIN-103Study of the Research Medicine CIN-103 in Adults with Irritable Bowel Syndrome with Predominant Diarrhea (IBS-D).
Sponsor:
CinPhloro Pharma, LLC
Location:
Code:
NCT06153420
Conditions
Irritable Bowel Syndrome with Diarrhea
Eligibility Criteria
Sex: All
Age: 18+
Healthy Volunteers: Not accepted
Interventions
CIN-103
Placebo
RO7790121A Study to Assess the Safety, Pharmacokinetics, and Activity of RO7790121 in Participants With Advanced MASH Liver Fibrosis
Sponsor:
Hoffmann-La Roche
Location:
Code:
NCT06903065
Conditions
MASH
Eligibility Criteria
Sex: All
Age: 18 - 70+
Healthy Volunteers: Not accepted
Interventions
RO7790121
PegozaferminA Study to Evaluate the Efficacy and Safety of Pegozafermin in Participants With Compensated Cirrhosis Due to MASH
Sponsor:
89bio, Inc.
Location:
Code:
NCT06419374
Conditions
Metabolic Dysfunction-Associated Steatohepatitis (MASH) / Nonalcoholic Steatohepatitis (NASH) With Compensated Cirrhosis
Eligibility Criteria
Sex: All
Age: 18 - 70+
Healthy Volunteers: Not accepted
Interventions
Pegozafermin
Placebo
Talquetamab, Daratumumab, PomalidomideA Study Comparing Talquetamab in Combination With Daratumumab or in Combination With Daratumumab and Pomalidomide Versus Daratumumab in Combination With Pomalidomide and Dexamethasone in Participants With Multiple Myeloma That Returns After Treatment or is Resistant to Treatment
Sponsor:
Janssen Research & Development, LLC
Location:
Code:
NCT05455320
Conditions
Relapsed or Refractory Multiple Myeloma
Eligibility Criteria
Sex: All
Age: 18+
Healthy Volunteers: Not accepted
Interventions
Talquetamab
Daratumumab
Pomalidomide
Dexamethasone
TarlatamabStudy Evaluating Tarlatamab After Chemoradiotherapy in Limited-Stage Small-Cell Lung Cancer (LS-SCLC)
Sponsor:
Amgen
Location:
Code:
NCT06117774
Conditions
Limited Stage Small Cell Lung Cancer
Small Cell Lung Cancer
Eligibility Criteria
Sex: All
Age: 18+
Healthy Volunteers: Not accepted
Interventions
Tarlatamab
Placebo
HZN-1116A Phase 2 Study to Investigate Efficacy and Safety of HZN-1116 in Participants With Sjogren's Syndrome
Sponsor:
Amgen
Location:
Code:
NCT06312020
Conditions
Sjogren's Syndrome
Eligibility Criteria
Sex: All
Age: 18 - 70+
Healthy Volunteers: Not accepted
Interventions
HZN-1116
Placebo
Sacituzumab Tirumotecan & PembrolizumabSacituzumab Tirumotecan (MK-2870) Plus Pembrolizumab Versus TPC in TNBC Who Did Not Achieve pCR (MK-2870-012)
Sponsor:
Merck Sharp & Dohme LLC
Location:
Code:
NCT06393374
Conditions
Triple-Negative Breast Cancer
Eligibility Criteria
Sex: All
Age: 18+
Healthy Volunteers: Not accepted
Interventions
Pembrolizumab
Sacituzumab tirumotecan
Capecitabine